AAREYDRUGS — Aarey Drugs and Pharmaceuticals Income Statement
0.000.00%
- IN₹1.58bn
- IN₹1.96bn
- IN₹3.96bn
- 40
- 38
- 40
- 31
Annual income statement for Aarey Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3,001 | 3,484 | 4,927 | 4,190 | 3,956 |
Cost of Revenue | |||||
Gross Profit | 99.1 | 106 | 206 | 151 | 137 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,978 | 3,447 | 4,834 | 4,124 | 3,929 |
Operating Profit | 23.4 | 37.2 | 92.8 | 66 | 27.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 72.4 | 83 | 100 | 60.1 | 53.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 57.9 | 65.1 | 65.4 | 37.7 | 46.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 57.9 | 65.1 | 65.4 | 37.7 | 46.8 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 57.9 | 65.1 | 65.4 | 37.7 | 46.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.48 | 2.79 | 2.72 | 1.5 | 1.84 |
Dividends per Share |